STOCKS TELEGRAPH

Author: ST Staff

Celldex Therapeutics (CLDX) stock Surged A Staggering 736% In The Previous Year

Celldex Therapeutics, Inc. (CLDX) share price soared an incredible 736% last year, with a 19% gain in the last three months. However, the share price still remains 56% lower than three years ago. CLDX did not make any profit in the last 12 months and saw its revenue grow by 1.8%. The 5-year annualized loss of 13% further halted the financial surplus for the company with many investors skeptical about the further purchase of CLDX shares.

CLDX has also opened options for new contracts such as the put contract which has a minimum bid of $3.20 So If a potential investor was to sell-to-open a put contract, they will be buying the stock for $25.00 and collecting the premium as well, putting the cost of the shares at $21.80 in addition to the brokerage fee. This may be considered a great alternative for the investor to buy a share directly for $26.37.

Why Celldex Therapeutics (CLDX) Stock Plummeted Today

Shares of Celldex Therapeutics (NASDAQ: CLDX) plummeted 34.1% on Monday. The shares tumbled as Celldex reported results from a phase 1b study of CDX-0159 to treat people affected with chronic inducible urticaria (CIndU), a condition that has infected 0.5% of the total population. Celldex stated that 80% of patients who were evaluated for a minimum 2 of weeks after treatment with CDX-0159 experienced an immune response, However, the positive news was overshadowed by concerns about the safety profile of the drug as the company reported one patient to have been unconscious followed by shivering and sweating.

The company is expected to complete their phase 1b clinical trials in the upcoming weeks and may also report results of the phase 1b study by the end of the year.

Conclusion

Celldex Therapeutics focuses on developing several immunotherapy technologies for diseases such as Cancer and chronic inducible urticaria. A 736% has profited the shareholders immensely however many investors are skeptical about the sustainability of the increase. Furthermore, safety concerns about their biopharmaceutical products and a consistent annualized loss has halted the company stock price to further skyrocket.

March 30, 2021
Millendo Therapeutics, Inc. (MLND) stock plunged in the recent trading session: here’s why

Millendo Therapeutics, Inc. stock currently traded at $1.52 which is a 30.28% downward movement, at the time of writing. The MLND stock previously closed at $2.18.

The news that comes adjacent to the recent pattern of stock of movement is the announcement of a merger between Millendo Therapeutics, Inc. (MLND) and Tempest Therapeutics.

Operational work and recent programs of Millendo Therapeutics, Inc

Millendo is a biopharmaceutical company that primarily focuses on approaching endocrine diseases’ treatment in an innovative way especially. The company specifically focuses on unmet requirements of the medical field for endocrinal disease treatments.

Operational work and recent programs of Tempest Therapeutics, Inc

Tempest Therapeutics is a clinical-stage oncology company that specializes in focusing on small molecules. This is done for the purposes of hybridizing targeted and immune-mediated mechanisms with the aim to treat a significant range of tumors.

Currently, the clinical-stage oncology company has two novel programs in its pipeline. These are TPST-1495 and TPST-1120 which are progressing through phase 1 studies. These studies are designed to treat both agents as monotherapies and in combination with other approved agents. Furthermore, Tempest is in the process of designing an inhibitor of TREX-1. TREX-1 inhibitor will have properties of a double-stranded DHA exonuclease which can trigger the activation of an innate immune response pathway.

The definitive agreement details behind the merger

Under the definitive agreement, the biopharmaceutical company Millendo Therapeutics (MLND) will be merged with Tempest in an all-stock transaction. The merged companies will then operate and retain the name Tempest Therapeutics and trade under the ticker name TPST.

The merged Tempest therapeutics (TPST) will combine all their focus on advancing the clinical-stage company’s oncology pipeline of small molecule therapeutics. This will further accelerate the program which is already recently collaborated with Roche to investigate TPS-1120 in a highly randomized frontline hepatocellular carcinoma study. Tempest is already advancing consistently on its oncology in this quarter and is expecting to accelerate the proprietary oncology programs it has next in line.

Financial agreements under the merger

Tempest (TPST) has successfully completed a deal agreement from a collective group of healthcare investors which include Versant Ventures, Eight Roads Ventures as well as 7 more investors valuing the deal at $30 million for its PIPE financing which will take place adjacent to the completion of the merger. The pre-merger Tempest (TPST) will hold 81.5% of the merged company while Millendo (MLND) will hold the rest. The merger agreement is expected to close in the first half of 2021.

March 29, 2021
FLY Leasing Inc. (FLY) stock rises during current market trading. Let’s find out why?

FLY Leasing Inc. (FLY) stock surges by 26.08% during current market trading after Carlyle Group Inc. has decided to buy Fly Leasing, taking the aircraft leasing business private in a $2.36 billion contract. FLY Leasing is a firm that invests in aircraft leasing. Its fleet consists of 110 flights, the bulk of which are Airbus A320 and Boeing 737 aircraft. FLY does not run its own fleet; instead, BBAM, a leasing management company, manages and executes leases.

What is happening?

According to a press release issued on Monday, Carlyle will pay $17.05 per share in cash for FLY also adding 84 aircraft to Carlyle’s commercial aviation investment and servicing arm. The agreement will probably close in the third quarter of 2021. The sale of FLY follows AerCap Holdings NV’s $30 billion purchase of General Electric Co.’s plane-leasing arm. Although air travel is steadily recovering since the leasing companies have suffered a lot due to the Covid-19 pandemic. They play an important financial role in keeping deliveries going, mostly via sale-leaseback arrangements that provide airlines with much-needed cash.

Furthermore,

Carlyle Aviation Partners, which is part of Carlyle’s global credit business, has $6.1 billion of assets and over 90 employees, and offices in the United States, Ireland, and Singapore. With 93 airline licensees in 53 countries, Carlyle owns, manages, or plans to buy 246 aircraft. The shares of Fly Leasing, which are listed on the New York Stock Exchange and are headed by former Aer Lingus chairman Colm Barrington, have increased by 90 percent in the last year.

Chief Executive of FLY Colm Barrington said that this deal represents good value for FLY shareholders especially when airlines are facing an extremely challenging environment and smaller aircraft lessors are disadvantaged in the debt markets.

March 29, 2021
Vipshop Holdings Limited (VIPS) stock plunged in the current market trading session: here’s why

VIPS stock is currently being traded at $29.82 which is a 4.33% downward movement. The stock previously closed at $31.19.

What is behind the block trade?

The recent negative pattern of the stock-movement is due to the sell-off behavior of US-listed shareholding in Chinese technology companies. Traders have braced themselves for volatility in the US-equities market following the $20 billion worth of trades blocked on Friday. This has really shaken investor’s comfort in investing in the Chinese tech stock as SEC has threatened the delisting of such firms from American exchanges.

The fear and speculation for de-listing of companies started stirring around 24^th March after US Securities and Exchange Commission adopted a law that was passed by former President Trump called the Holding Foreign Companies Accountable Act. The law also requires the Chinese companies to present the names of each Board member who is a member of the Chinese Communist Party.

Stock dump and initial block trade

The stock dump has come from Archegos Capital Management LLC which consists of the family office of Bill Hwang. They dumped shares of not only Chinese tech firms but also US media conglomerates. It has been reported that the initial block trades have come from Goldman Sachs as well as Morgan Stanley. However, majority of those block trades have been rebounded apart from ViacomCBSinc and Discovery Inc.

Stanley sold a large block of 45 million shares of ViacomCBS on Sunday. Similarly, Goldman Sachs sold the shares of Vipshop Holdings Ltd, ViacomCBSInc, IQiyiinc, Baidu, and Tencent Music Entertainment Group for a total worth of $10.5 billion.

Significant observation and investment behavior adopted now by investors

One main observation is being made around by analysts and portfolio fund managers that they are not sure if additional block trades will take place but the fear still looms over the market over its speculation. However, they are assuring readers and investors that none of the sell-downs are related to the fundamentals, performance, and outlook of the Chinese tech companies.

The fear and speculation of a block trade is stacking up with the traditional end-of-quarter volatility that causes sharp swings on stocks while triggering selling sentiment from other funds. However, a strategy is being implied by investors where they realize that the fundamentals of these companies are essentially the same, while this de-listing is an exaggeration that will dim down in the future. Meanwhile, that happens these Tech stocks are undervalued as their stock price keeps dropping which makes them a buying option for some long-term investors.

March 29, 2021
iQIYI (IQ) stock soared today in the current trading session; Here’s why

The iQIYI (IQ) stock recently traded at $17.78 which is a 1.46% upward movement. The IQ stock previously closed at $17.43.

What is the recent news behind this trading behavior?

While there is no news on today’s market that could correlate to the movement in the current trading session, iQIYI(IQ) had announced previously on 28^th March, the streaming of highly successful THE9’s online concert performance over its streaming platform.

Glimpse into iQIYI’s fundamentals

iQIYI (IQ) is an internet entertainment and video streaming service company. iQIYI is well known to lead in its services and features of original content making. The entertainment provided on this platform is reviewed as highly engaging and popular enough to engage a huge online audience for it. The video streaming company garnered an average total of 479.8 million Monthly Active Users while the Daily Active Users consist of 115.6 million for 2020. iQIYI recently invested 100 RMB to enhance its film quality production, visual-effects, hyper-realistic interactive technology and live stream. This investment was highly rewarded on 26^th and 27^th March when iQIYI held the XR live concert featuring THE9 with fans highly excited for this experience.

Tell me more about the TECH9 extended reality concert

What broke the internet over the weekend was that iQIYI was able to provide a lively and hyper-realistic online experience for its users and THE9 fans who were stuck at home in the pandemic. IQ delivered what is considered an extended reality (XR) live concert screened through a LED stage with photorealistic virtual reality presentation. The overall experience was futuristic and one-of-a-kind experience.

The immediate success of the concert was shared along with the highly enthusiastic and excited fans who shared their views online saying that “immersive experience of the concert was beyond-expectation and highly exciting performance by THE9 was very thrilling”. The fans could interact with their idols through either virtually having their seat placed in front of the performance or given an online invitation to be “on-stage”. At the same time, the visual setting for each performance was uniquely executed with adaptation of different cinematic-led background and lighting adjustments.

Does this performance bear good news for the IQ stock?

iQIYI’s (IQ) business boomed due to the pandemic and it utilized this opportunity fully through clever business approach and investment that combined virtual reality and online interactions. We know technology is highly advancing but to be able to market it in the way iQIYI (IQ) does, is what sets the trend pattern for future.

Combining these cutting-edge experiences, innovative content, and high quality tech will provide additional benefits in the form of greater operational performance and increased value of IQ stock. Pioneering this online entertainment trend and sustaining it throughout the newer generation of entertainment will present IQ stock as a solid long term investment.

March 29, 2021
Humanigen, Inc. (HGEN) stock Continues to Gain today: Things you Need to Know

Humanigen, Inc. (HGEN) announced positive phase 3 Topline results of lenzilumab, humanized monoclonal antibody, after which the HGEN stock price saw a surge of 45.42% today’s session to reach $20.34 a share as of this writing. HGEN stock was also green in the previous trading session and at closing, it was up by 1.67% with a $13.99 per share price. Let’s understand more about today’s HGEN news.

A deep look at Clinical Results.

Humanigen was performing a phase three clinical trial of lenzilumab for the past couple of months. The study was based on the evaluation of efficacy and safety results of lenzilumab in the hospitalized patients suffering from COVID-19. According to the phase three results, the patients who had received lenzilumab along with steroids or remdesivir were more likely to survive without the use of invasive mechanical ventilation (IMV) as compared to the patients who did not receive the lenzilumab.HGEN was happy to see these results.

Mayo Clinic was the part of this study and Zelalem Temesgen, MD, who is a professor at Mayo Clinic, was serving as the Principal investigator of this trial. According to him, lenzilumab proved to be much effective in its results as it significantly reduced the chances of one’s going on a ventilator. Andrew Badley, MD, a professor of Infectious Diseases, showed much excitement about these results. He said that lenzilumab would be an important part of Mayo Clinic in future trials if it gets approval from U.S. Food and Drug Administration.

Next Goal of Humanigen, Inc.

After getting exceptional results in phase three clinical trial of lenzilumab, Humanigen’s management is planning to apply for the grant of getting Emergency Use Authorization(EUA) by the Food and Drug Administration. Humanigen also sharing these results with different governmental agencies of the U.S as well as authorities of many countries in the globe.

Financial View of HGEN stock

On March 10, 2021, Humanigen stock announced its fourth quarter and fiscal year 2020 results according to which HGEN stock recorded the net loss of $89.5 million or $2.42 per share in 2020 as compared to a net loss of $10.3 million or $0.46 per share in 2019. This increase was mainly due to a massive increase in the research and development expenses in 2020. The R&D expenses for 2020 were $72.7 million while these were just $2.6 million in 2019. $67.7 million of cash and cash equivalents were recorded at the end of 2020.

Conclusion:

Considering the market sentiment, HGEN stock is in a good position as investors are responding to the news announced by Humanigen, Inc.Positive results of the phase three study would prove to be fruitful for the HGEN stock in the future. Recent earnings report shows that Humanigen has progressed over the year. Hence HGEN stock can be a good bet in the long run.

March 29, 2021
BOQI International Medical Inc. (BIMI) stock rises during pre-market trading. Why is it so?
BOQI International Medical Inc. (BIMI) stock soared by 4.82% in the last trading close while the BIMI stock price continued to rise by 4.60% in the pre-market trading session. As of now, any recent news does not follow the rise in BIMI stock. BOQI International Medical is dedicated towards health industry with its special focus on providing healthcare products and related services.

Recent Past Developments

Memorandum of Understanding
- BIMI announced that on March 24, 2021, BOQI International Medical signed a Memorandum of Understanding with two independent sellers with the goal of attaining three hospitals: Yunnan Yuxi Minkang Hospital, Wuzhou Qiangsheng Hospital, and Suzhou Eurasia Hospital. All three companies’ shares are owned entirely by the Sellers.
BOQI International Medical Inc. and the Sellers have reached a tentative agreement on mergers and acquisitions in accordance with the MOU. They have decided to sign a Stock Purchase Agreement after fulfilling the requisite hospital tests and evaluations. BOQI International Medical would pay the consideration in cash or BIMI common stock at a price of $3.00 per share after signing the Agreement. Also the sellers have agreed to give BIMI $75,000 as a deposit in three days right after signing the MOU.

Signed a New Offering
- On March 1, 2021 BOQI International Medical announced that they have finalized a private placement of $5,400,000 of its senior convertible notes to two institutional investors. The private placement was closed on February 26, 2021. BIMI and the Investors decided to lift the maximum amount of Convertible Notes that can be bought under the Securities Purchase Agreement from $2,100,000 to $5,400,000 at a 16.67 percent original issue discount ($4,500,000 net).
BIMI will also give warrants to the Investors to buy an additional 720,000 shares of BIMI’s common stock at a price of $2.845 per share. The conversion of $3.3 million in newly issued Convertible Notes and the exercise of newly issued Warrants are also open to stockholder and regulatory approvals, as well as a beneficial ownership restriction. BOQI International Medical is planning to utilize the net amount generated through this offering for general corporate and working capital purposes. And lastly FT Global Capital is working as the exclusive placement agent for the offering.
March 29, 2021
SeaChange International Inc. (SEAC) stock rises during current market trading. Why is it so?

SeaChange International Inc. (SEAC) stock plunged by 2.83% in the last trading closed whereas the SEAC stock is on a rise by 25.24% during current market trading after SEAC announced that they have signed a huge multi-year deal of millions of dollars with one of the biggest broadband service providers in USA. SeaChange International is a publicly-traded multinational video distribution software provider. Video preparation, back-office, media resources management, dynamic advertising insertion, analytics, and a user interface are all part of SeaChange’s “System.

What is happening?

SeaChange’s technology has allowed this major broadband service provider to adapt to technological advances in the industry for over 15 years. Under the terms of the new agreement, SEAC would collaborate with the customer to shift its infrastructure to a virtual network that will reduce the operator’s hardware footprint and also increase the service availability. By utilizing SeaChange’s technology to enhance the management of its Ad Servers through remote operator device installations and hardware health management, the customer’s TV service offering can be more monetized.

Furthermore,

Christoph Klimmer the SVP of Global Sales and Marketing, SEAC said that Long-term customers, such as this major broadband service provider, are growing their use of SEAC’s technology and are rapidly gaining from their ad technology, which enables cross-platform and dynamic advertisement solutions for cable and IP video distribution. He also added that this significant contract between SEAC and the major broadband service provider includes both license and service parts and has one of the highest average annual prices of any North American contract in over two years. Also, the success illustrates SeaChange’s status as a trusted partner to the world’s most prominent companies, demonstrating SEAC’s efficient go-to-market strategy and comprehensive approach to selling the full value of our software and services.

March 29, 2021
Why Universe Pharmaceuticals Inc (UPC) stock rallied in Pre-Market today?

Shares of Universe Pharmaceuticals Inc (UPC) were soaring in Monday’s pre-market trading session. UPC stock price saw a boom of 83.54% in today’s pre-market to reach $7.47 a share as of this writing. The previous closing price of UPC stock was $4.07 representing a 0.49% gain. Let’s try to figure out the reason behind this bull.

What’s happening?

We find no news in today’s date by the UPC stock, no earnings report or analyst upgrades to justify this bull however on March 26, 2021, Univest Securities, LLC did announce the closure of an initial public offering (IPO) for its client Universe Pharmaceuticals Inc.This initial public offering of 5,000,000 ordinary shares was announced by the Universe Securities, LLC on March 23, 2021, at a public price of US$5.00 per ordinary share of the UPC stock.

This IPO resulted in US$25 million in the aggregate gross proceeds without deducting the offering-related expenses and the underwriting discounts. Furthermore, the underwriter has been granted a 45-day option to buy additional 750,000 shares of UPC stock under this public offering. The trading of ordinary shares of UPC stock began on March 23, 2021.

UPC stock Future Plans

Universe stock is planning to make use of these proceeds in various of its operational areas as well as for the growth in its manufacturing facilities. This revenue will help the UPC stock for the advancement in its research and development fields and will support the brand awareness, marketing, and advertisement of the Universe Stock. Some part of this amount will be used for UPC’s working capital and general corporate purposes.

About Universe Pharmaceuticals Inc

Universe Pharmaceuticals INC(UPC), a subsidiary of Sununion Holding Group Limited, is mainly working in the areas of research, development, marketing, and selling of traditional Chinese Medicine products in the Republic of China. Main focus of the UPC is the treatment of chronic diseases in the elders.UPC was founded in 2019 and its headquarter are located in Jiangxi, China.

Conclusion:

UPC stock is enjoying the bullish sentiment in the stock market despite the absence of any specific news by the Universe stock.UPC management is well aware of the future goals related to its development and expansion. Hence it is better for investors eyeing UPC stock to perform both technical and fundamental analysis before taking any decision.

March 29, 2021
Eastside Distilling Inc. (EAST) stock rises during pre-market trading. Here’s to know why?
Eastside Distilling Inc. (EAST) stock showed a rise of 0.56% in the last trading closed while the EAST stock continued to rise by 6.08% in the pre-market trading session. Eastside Distilling has not reported any recent news hence we will look at the recent past developments to see any relevance with the current EAST share price. Since 2008, Eastside Distilling has been making exceptionally good craft spirits in Portland, Oregon. The company is known for its award-winning product line, which includes Azuia Tequilas, Burnside Whiskeys, Hue-Hue Coffee Rum, and Portland Potato Vodkas.

IMPORTANT DEVELOPMENTS
- On March 26, EAST announced that Liz Levy-Navarro has been appointed to the Eastside’s Board of Directors, since March 22, 2021. Ms. Levy-Navarro will chair the Compensation Committee and also work on the Audit, Nominating, and Corporate Governance Committees. Ms. Levy-Navarro has spent her career assisting market leaders in expanding their companies and brands as a CEO, public and private sector board member, consumer goods practice leader, and value creation specialist.
- On March 1, Eastside announced that with the new “Eastside Brand” and the new Eastside range of spirits products, Eastside is extending its premium spirits line. The Eastside unique products will focus on the Company’s passion to provide our loyal customers with the most creative, highest-quality, hand-crafted, small-batch products. Almost all of the items will be restricted and only available in a few locations. The product will ship in late March and should be on store shelves in April.
Conclusion

From the above mentioned positive developments in Eastside, it is possible that the current rise in EAST stock is because of the experienced working of Ms. Lis Levy-Navarro for Eastside, making sure that the investors feel interested and comfortable in making long-term investments in EAST stock. Also, the launch of a new brand by Eastside is a great step towards progress.
March 29, 2021